Changes in vitamin D metabolites during teriparatide treatment
Bone, 04/30/2012
Clinical Article
Cosman F et al. – Treatment with teriparatide increases 1,25(OH)2D concentrations and decreases 25(OH)D concentrations.
Methods- Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000mg and vitamin D 400–1200IU.
- Serum concentrations of 1,25(OH)2D and 25(OH)D were measured.
- In women (N=336), median 1,25(OH)2D concentrations at 1month increased from baseline by 27% (P<0.0001) in the teriparatide group versus –3% (P=0.87) in the placebo group (between group P<0.0001).
- At 12months, the increase was 19% (P<0.0001) in the teriparatide group versus –2% (P=0.23) in the placebo group (P<0.0001).
- Median 25(OH)D concentrations at 12months decreased by 19% (P<0.0001) in the teriparatide group versus 0% (P=0.13) in the placebo group (P<0.0001).
- In men (N=287), median 1,25(OH)2D concentrations at 1month increased by 22% (P<0.0001) in the teriparatide group versus 0% (P=0.99) in the placebo group (P<0.0001).
- At 12months, the increase was 14% (P<0.0001) in the teriparatide group versus 5% (P=0.004) in the placebo group (P=0.17).
- Median 25(OH)D concentrations at 12months decreased by 11% (P=0.001) in the teriparatide group versus an increase of 1% (P=0.20) in the placebo group (P=0.003).
